Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9856228 | 1.00 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL29007788 | 0.93 | — | — | |
| SCHEMBL10270032 | 0.88 | — | — | |
| Bicarbonate SCHEMBL3150969 | 0.78 | MEN1 (0.30) | ALDH1A1 | |
| SCHEMBL11219346 | 0.78 | — | — | |
| SCHEMBL34468849 | 0.78 | — | — | |
| SCHEMBL11241824 | 0.77 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL841625 | 0.77 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL11215336 | 0.77 | — | — | |
| SCHEMBL11339124 | 0.73 | ALDH1A1 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038249-B1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM SPA (IT) | 2013-09-11 | — | — | EP | claimed |
| US-8143443-B2 | Process for preparing gabapentin | ZACH SYSTEM S.P.A. (IT) | 2012-03-27 | — | — | US | claimed |
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2010-02-04 | — | — | US | claimed |
| EP-2038249-A1 | PROCESS FOR PREPARING GABAPENTIN | ZaCh System S.p.A. (IT) | 2009-03-25 | — | — | EP | claimed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | claimed |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114727974-A | HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4003319-A2 | HDAC6 INHIBITORS AND USES THEREOF | Eikonizo Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021021979-A2 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-101484413-B | Process for preparing gabapentin | ZACH SYSTEM SPA | 2014-05-14 | — | — | CN | disclosed |
| EP-2038249-B1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM SPA (IT) | 2013-09-11 | — | — | EP | disclosed |
| CN-101484413-A | Process for preparing gabapentin | ZACH SYSTEM SPA (IT) | 2009-07-15 | — | — | CN | disclosed |
| EP-2038249-A1 | PROCESS FOR PREPARING GABAPENTIN | ZaCh System S.p.A. (IT) | 2009-03-25 | — | — | EP | disclosed |
| EP-2038249-A1 | PROCESS FOR PREPARING GABAPENTIN | ZaCh System S.p.A. (IT) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004115-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2008-01-10 | — | — | WO | disclosed |
| US-5075032-A | Electrooptics, switches, displays | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-12-24 | — | — | US | disclosed |
| US-4886620-A | Smectic liquid-crystalline phases | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ALDH1A1 901/4885 |
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | GABRB1, GABRG1, OGDH | ALDH1A1 55/4885 |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC11 | ALDH1A1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.